Figure 4.

CNX-012-570 reduces serum triglyceride, total cholesterol and has a potential to reduce macro-vesicular steatosis in DIO mice. (A) Fasting serum triglycerides were measured once in two weeks. (B) At week 8, serum fed cholesterol was measured. (C & D) After the study termination, liver cholesterol and triglyceride levels were measured. (E) Histopathological analysis of formalin fixed liver sections after H&E staining. (F) After the study termination, mRNA levels of liver SREBP1c, MCP1 and APOB100 were measured as mentioned in materials and methods. Clear bar-lean control, black bar-HFD control, grey bar-CNX-012-570 treatment (3 mg/kg, orally once a day). All the values are expressed as Mean ± SEM. Statistical comparison between control and treatment group was conducted by One-way ANOVA followed by Dunnett’s test or students unpaired t-test as appropriate (*P < 0.05, ** P < 0.01 and *** P < 0.001).

Anil et al. Cardiovascular Diabetology 2014 13:27   doi:10.1186/1475-2840-13-27
Download authors' original image